Inhibrx Biosciences, Inc. (INBX) vs Maze Therapeutics, Inc. (MAZE)

Inhibrx Biosciences, Inc. and Maze Therapeutics, Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Maze Therapeutics, Inc. are of similar size ($1.5B and $1.5B). Across the 9 metrics below, Inhibrx Biosciences, Inc. leads on 5 and Maze Therapeutics, Inc. on 4.

Valuation

Metric INBX MAZE Biotechnology median
P/E n/m n/m 7.88
P/S 495.33 n/m 11.47
P/B n/m 3.39 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 508.96 n/m 10.73
Earnings yield (8.91%) (9.67%) (28.84%)
Free cash flow yield (8.45%) (6.95%) (23.03%)

Profitability

Metric INBX MAZE Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1,773.60%) (37.35%) (57.72%)
Return on assets (75.44%) (31.99%) (49.22%)
Return on invested capital 0.00% (112.36%) 0.00%

Growth

Metric INBX MAZE Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) (108.03%) (344.00%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric INBX MAZE Biotechnology median
Debt to equity (3.33) 0.09 0.00
Current ratio 5.07 18.31 4.73
Net debt to EBITDA 0.18 2.43 0.96

Dividend

Metric INBX MAZE Biotechnology median
Dividend yield — — 2.10%
Payout ratio — — 0.00

Size

Metric INBX MAZE Biotechnology median
Market cap 1.48b 1.48b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack